Cipla (CIPLA) Q3 25/26 earnings summary

Executive summary

• Q3 FY26 revenue was INR 7,074 crore, flat year-over-year, with strong 10% YoY growth in India, led by chronic therapies and consumer health, offset by declines in U.S. generics and supply disruptions.

• Strategic launches included Afrezza (inhaled insulin), Mounjaro (tirzepatide), and exclusive marketing/distribution partnerships with Pfizer and Eli Lilly; acquisitions of Inzpera Healthsciences and Esperer Onco Nutrition expanded the wellness portfolio.

• U.S. business was impacted by lower Lenalidomide and lanreotide sales, though base business (ex-Lenalidomide) grew double digits YoY; Albuterol maintained #1 market share.

• Lanreotide supply disruption due to FDA observations at partner site, with resupply expected H1 FY27.

• Unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025 were approved and released.

Financial highlights

• EBITDA margin (excluding other income) was 17.7%, with EBITDA at INR 1,255 crore, and PAT at INR 676 crore (9.6% of sales), both declining YoY due to lower generic revenues and product mix.

• Gross margin stood at 62.8%, impacted by Lenalidomide decline and R&D/API material costs.

• R&D investment was INR 494 crore (7% of revenue), up YoY, focused on pipeline development.

• Net cash position at INR 10,229 crore; debt (including leases) at INR 489 crore as of Dec 31, 2025; cash balance stood at INR 10,718 crore.

• Exceptional item of INR 276 crore recognized due to increased employee benefit liabilities from new labour codes.

Outlook and guidance

• FY26 EBITDA margin guidance revised to ~21% due to lower lanreotide and Lenalidomide revenues.

• U.S. revenue guidance for FY27 to be revised downward due to lanreotide disruption; new launches expected to offset declines.

• Strategic focus on expanding therapy coverage, scaling consumer wellness brands, and execution in India.

• Acquisition of perpetual rights to manufacture and market Galvus brands for INR 1,107 crore, effective 1 January 2026, expected to strengthen diabetes portfolio.

• Acquisition of Inzpera Healthscience Limited completed in December 2025 for INR 110.65 crore.